Clinical effect analysis on excision surgery combined with postoperative medication adenomyosis

In: Guoji yiyao weisheng daobao · 2012 · vol. 18(12) , pp. 1743–1745 · doi:10.3760/cma.j.issn.1007-1245.2012.12.022 · W3029812735
article OA: closed CC0
View on OpenAlex View at publisher

Abstract

Objective To investigate the curative effects of uterine adenomyosis lesion resection combined with different drug treatment,providing clinical basis for the treatment.Methods All patients were randomly divided into group A,B and C according to different treatments,surgery plus Diphereline group,surgery plus oral contraceptive group and surgery alone group.VAS scores,dysmenorrhea,and complications of the three groups were observed and compared.Results The pre-treatment VAS scores of the groups had no significant difference (P>0.05).The VAS scores of three groups after treatment were significantly reduced,and the surgery plus Diphereline group scored significantly lower than the other two groups,the difference was statistically significant (P<0.05).All patients' dysmenorrhea in sttrgery plus Diphereline group relieved,and there was a statistically significant difference among the three groups (P<0.05).Surgery plus Diphereline group was superior to the other two groups.No serious complications happened in three groups.Conclusion Surgery plus Diphereline treatment to uterine adenomyoma patients can effectively improve dysmenorrhea,menorrhagia and other symptoms,which is a safe and effective method for fertility patients. Key words: Adenomyosis; Surgery; Treatment; Diphereline

My notes (saved in your browser only)

Condition tags

adenomyosisdysmenorrhea

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-06-04T00:00:01.174412+00:00
License: CC0 · commercial use OK